National Audit of Seizure Management in Hospitals (NASH): Results of the National Audit of Adult Epilepsy in the UK
Overview
Affiliations
Objectives: About 100,000 people present to hospitals each year in England with an epileptic seizure. How they are managed is unknown; thus, the National Audit of Seizure management in Hospitals (NASH) set out to assess prior care, management of the acute event and follow-up of these patients. This paper describes the data from the second audit conducted in 2013.
Setting: 154 emergency departments (EDs) across the UK.
Participants: Data from 4544 attendances (median age of 45 years, 57% men) showed that 61% had a prior diagnosis of epilepsy, 12% other neurological problems and 22% were first seizure cases. Each ED identified 30 consecutive adult cases presenting due to a seizure.
Primary And Secondary Outcome Measures: Details were recorded of the patient's prior care, management at hospital and onward referral to neurological specialists onto an online database. Descriptive results are reported at national level.
Results: Of those with epilepsy, 498 (18%) were on no antiepileptic drug therapy and 1330 (48%) were on monotherapy. Assessments were often incomplete and witness histories were sought in only 759 (75%) of first seizure patients, 58% were seen by a senior doctor and 57% were admitted. For first seizure patients, advice on further seizure management was given to 264 (27%) and only 55% were referred to a neurologist or epilepsy specialist. For each variable, there was wide variability among sites that was not explicable. For the sites who partook in both audits, there was a trend towards better care in 2013, but this was small and dwarfed by the intersite variability.
Conclusions: These results have parallels with the Sentinel Audit of Stroke performed a decade earlier. There is wide intersite variability in care covering the entire care pathway, and a need for better organised and accessible care for these patients.
Carpio A, Salgado C, DiCapua D, Fleury A, Suastegui R, Giagante B Epilepsia Open. 2024; 9(2):776-784.
PMID: 38366910 PMC: 10984322. DOI: 10.1002/epi4.12900.
Asano Y, Fujimoto A, Hatano K, Sato K, Atsumi T, Enoki H PLoS One. 2023; 18(8):e0290783.
PMID: 37643171 PMC: 10464987. DOI: 10.1371/journal.pone.0290783.
Mbizvo G, Schnier C, Simpson C, Duncan S, Chin R Brain. 2022; 146(6):2418-2430.
PMID: 36477471 PMC: 10232261. DOI: 10.1093/brain/awac463.
Noble A, Mason S, Bonnett L, Reuber M, Wright J, Pilbery R BMJ Open. 2022; 12(11):e069156.
PMID: 36375988 PMC: 9668054. DOI: 10.1136/bmjopen-2022-069156.
Taylor C, Tudur-Smith C, Dixon P, Linehan C, Gunko A, Christensen J Eur J Neurol. 2022; 29(7):1873-1884.
PMID: 35340074 PMC: 9324798. DOI: 10.1111/ene.15336.